6L60.F Senseonics Holdings Inc.
- Market cap
- EUR 468M
- P/E
- -
- P/B
- 4.93x
- ROE
- -174.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6L60.F undervalued?
Graham numberThe Graham number of Senseonics Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Senseonics Holdings Inc. fundamental analysis
No fundamental analysis for Senseonics Holdings Inc. yet.
Senseonics Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Senseonics Holdings Inc.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a…
Full company profileSenseonics Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Senseonics Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 13.7M | 16.4M | 22.4M | 22.5M | 35.3M | 61.0M |
| Gross Profit | -811K | 2.73M | 3.09M | 533K | 15.8M | 36.8M |
| Operating Income | -57.2M | -68.6M | -75.6M | -74.8M | -68.3M | -133M |
| EBITDA | - | 162M | -48.0M | -68.7M | -62.7M | -127M |
| Net Income | -302M | 142M | -60.4M | -78.6M | -69.1M | -136M |
| EPS | -0.68 | 0.30 | -0.11 | -0.13 | -1.67 | -2.48 |
| Balance Sheet | ||||||
| Total Assets | 199M | 178M | 138M | 100M | 126M | 163M |
| Total Liabilities | 384M | 180M | 102M | 117M | 65.2M | 84.9M |
| Shareholders' Equity | -186M | -2.58M | 35.8M | -16.6M | 61.0M | 77.6M |
| Cash & Short-term Investments | 33.5M | 35.8M | 75.7M | 74.6M | 40.2M | 47.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -56.1M | -66.3M | -70.2M | -60.5M | -59.1M | -127M |
| Capital Expenditure | 210K | 312K | 350K | 2.24M | 1.12M | 751K |
| Free Cash Flow | -56.3M | -66.6M | -70.5M | -62.7M | -60.2M | -128M |
| Ratios | ||||||
| ROE | - | - | -168.7% | - | -113.2% | -174.7% |
| ROA | -152.1% | 80.0% | -43.7% | -78.3% | -54.7% | -83.5% |
| Net Profit Margin | -2,211.9% | 867.2% | -269.7% | -349.8% | -196.0% | -222.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Senseonics Holdings Inc. dividends
Senseonics Holdings Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Oct 20, 2025.
Who owns Senseonics Holdings Inc.
- Insiders 9.87%
- Institutions 40.10%
- Public & others 50.03%
- Shares outstanding 52.9M
- Free float 45.2M
Senseonics Holdings Inc. company profile
- Company name
- Senseonics Holdings Inc.
- Ticker
- 6L60.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 130
- Fiscal year end
- December
- Address
- 20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005
- Phone
- 301 515 7260
- Website
- senseonics.com
About Senseonics Holdings Inc.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings Inc. management
6- Dr. Timothy T. Goodnow Ph.D.President, CEO & Director · born 1962
- Mr. Frederick T. Sullivan CPACFO, Secretary & Treasurer · born 1982
- Dr. Mukul Jain Ph.D.Chief Operating Officer · born 1973
- Dr. Francine Ratner Kaufman M.D.Chief Medical Officer & Director · born 1951
- Mr. Brian B. HansenChief Commercial Officer & Director · born 1968
- Mr. Kenneth L. Horton J.D.General Counsel & Corporate Development Advisor · born 1967